In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 6 selected

Guidance programme

Showing 1 to 10 of 319

TitleTypeExpected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Technology appraisal guidanceTBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Technology appraisal guidanceTBC
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232Technology appraisal guidanceTBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354Technology appraisal guidanceTBC
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]Technology appraisal guidanceTBC
ALXN1840 for treating Wilson disease TS ID 9950Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All